| Version |
2.5 |
| Creation Date |
2005-06-13 13:24:05 |
| Update Date |
2009-06-23 18:06:21 |
| Primary Accession Number |
DB00328 |
| Secondary Accession Number |
|
| Name |
Indomethacin |
| Drug Type |
- Approved
- Investigational
- Small Molecule
|
| Description |
A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes. [PubChem] |
| Synonyms |
- IMN
- Indometacine
- Indometacyna
- Indomethacine
- Indomethacinum
- Indomethancin
- Indomethazine
- Indomethine
- Indometicina
- indomethacin
|
| Brand Names |
- Amuno
- Apo-Indomethacin
- Argun
- Arthrexin
- Artracin
- Artrinovo
- Artrivia
- Bonidin
- Bonidon
- Bonidon Gel
- Catlep
- Chibro-Amuno
- Chrono-Indicid
- Chrono-Indocid
- Confortid
- Dolcidium
- Dolcidium Pl
- Dolovin
- Durametacin
- Elmetacin
- Flexin Continus
- Hicin
- Idomethine
- Imbrilon
- Inacid
- Indacin
- Indaflex
- Indameth
- Indmethacine
- Indo-Lemmon
- Indo-Phlogont
- Indo-Rectolmin
- Indo-Spray
- Indo-Tablinen
- Indocid
- Indocid Pda
- Indocid Sr
- Indocin
- Indocin I.V
- Indocin I.V.
- Indocin Sr
- Indolar Sr
- Indomecol
- Indomed
- Indomee
- Indomethegan
- Indomo
- Indomod
- Indoptic
- Indoptol
- Indorektal
- Indoxen
- Inflazon
- Infrocin
- Inteban Sp
- Lausit
- Liometacen
- Metacen
- Metartril
- Methazine
- Metindol
- Miametan
- Mikametan
- Mobilan
- Novo-Methacin
- Novomethacin
- Nu-Indo
- Reumacide
- Rhemacin La
- Rheumacin La
- Sadoreum
- Tannex
- Vonum
|
| Brand Mixtures |
Not Available |
| Chemical IUPAC Name |
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid |
| Chemical Formula |
C19H16ClNO4 |
| Chemical Structure |
 |
| CAS Registry Number |
53-86-1 |
| InChI Identifier |
InChI=1/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)/f/h22H |
| InChI Key |
CGIGDMFJXJATDK-QWOVJGMICU |
| KEGG Drug |
D00141  |
| KEGG Compound |
C01926  |
| PubChem Compound |
3715  |
| PubChem Substance |
148696  |
| ChEBI ID |
5918  |
| PharmGKB ID |
PA449982  |
| HET ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
02143372  |
| RxList Link |
http://www.rxlist.com/cgi/generic/indometh.htm  |
| PDRhealth Link |
Not Available |
| Wikipedia Link |
http://en.wikipedia.org/wiki/Indomethacin  |
| FDA Label |
|
| Material Safety Data Sheet (MSDS) |
|
| Synthesis Reference |
Not Available |
| Average Molecular Weight |
357.7880 |
| Monoisotopic Molecular Weight |
357.0768 |
| State |
Solid |
| Melting Point |
158 oC |
| Experimental Water Solubility |
0.937 mg/L
Source: PhysProp
|
| Predicted Water Solubility |
2.40e-03 mg/mL
Calculated using ALOGPS
|
| Experimental LogP/Hydrophobicity |
3.4
Source: PhysProp
|
| Predicted LogP |
4.25
Calculated using ALOGPS
|
| Experimental LogS |
-4.62 [ADME Research, USCD] |
| Predicted LogS |
-5.17
Calculated using ALOGPS
|
| Experimental Caco2 Permeability |
-4.69 [ADME Research, USCD] |
| pKa/Isoelectric Point |
4.5 |
| Mass Spectrum |
Not Available
|
| MOL File |
Show | Download  |
| SDF File |
Show | Download  |
| PDB File |
Show | Download  |
| 2D Structure |
|
| 3D Structure |
|
| Experimental PDB ID |
Not Available |
| Isomeric SMILES |
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O |
| Canonical SMILES |
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O |
| Drug Category |
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-inflammatory Agents
- Cardiovascular Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Nonsteroidal Antiinflammatory Agents (NSAIDs)
- Tocolytic Agents
|
| ATC Codes |
|
| AHFS Codes |
|
| Indication |
For moderate to severe rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. |
| Pharmacology |
Indomethacin, a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. |
| Mechanism of Action |
Antiinflammatory effects of Indomethacin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. |
| Absorption |
Bioavailability is approximately 100% following oral administration and 80–90% following rectal administration. |
| Toxicity |
The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively. |
| Protein Binding |
97% |
| Biotransformation |
Hepatic. |
| Half Life |
4.5 hours |
| Dosage Forms |
| Form |
Route |
| Capsule |
Oral |
| Powder, for solution |
Intravenous |
| Suppository |
Rectal |
|
| Patient Information |
Show  |
| Contraindications |
Show  |
| Interactions |
Show  |
| Drug Interactions |
| Drug |
Interaction |
| Acebutolol |
Risk of inhibition of renal prostaglandins |
| Acenocoumarol |
The NSAID increases the anticoagulant effect |
| Alendronate |
Increased risk of gastric toxicity |
| Anisindione |
The NSAID increases the anticoagulant effect |
| Atenolol |
Risk of inhibition of renal prostaglandins |
| Betaxolol |
Risk of inhibition of renal prostaglandins |
| Bevantolol |
Risk of inhibition of renal prostaglandins |
| Bisoprolol |
Risk of inhibition of renal prostaglandins |
| Bumetanide |
The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic |
| Carteolol |
Risk of inhibition of renal prostaglandins |
| Carvedilol |
Risk of inhibition of renal prostaglandins |
| Cyclosporine |
Monitor for nephrotoxicity |
| Dicumarol |
The NSAID increases the anticoagulant effect |
| Diflunisal |
Diflunisal increases the effect and toxicity of indomethacin |
| Esmolol |
Risk of inhibition of renal prostaglandins |
| Ethacrynic acid |
The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic |
| Furosemide |
The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic |
| Labetalol |
Risk of inhibition of renal prostaglandins |
| Lithium |
The NSAID increases serum levels of lithium |
| Losartan |
Indomethacin decreases the effect of losartan |
| Methotrexate |
The NSAID increases the effect and toxicity of methotrexate |
| Metoprolol |
Risk of inhibition of renal prostaglandins |
| Nadolol |
Risk of inhibition of renal prostaglandins |
| Oxprenolol |
Risk of inhibition of renal prostaglandins |
| Penbutolol |
Risk of inhibition of renal prostaglandins |
| Pindolol |
Risk of inhibition of renal prostaglandins |
| Practolol |
Risk of inhibition of renal prostaglandins |
| Probenecid |
Probenecid increases the effect/toxicity of indomethacin |
| Propranolol |
Risk of inhibition of renal prostaglandins |
| Sotalol |
Risk of inhibition of renal prostaglandins |
| Timolol |
Risk of inhibition of renal prostaglandins |
| Torasemide |
The NSAID decreases the diuretic and antihypertensive effects of the loop diuretic |
| Triamterene |
Risk of acute renal impairment with this combination |
| Warfarin |
The NSAID increases the anticoagulant effect |
|
| Food Interactions |
- Avoid alcohol.
- Take with food or antacids to reduce irritation.
|
| Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Indomethacin Pathway |
SMP00104  |
|
|
| General References |
- HART FD, BOARDMAN PL: INDOMETHACIN: A NEW NON-STEROID ANTI-INFLAMMATORY AGENT. Br Med J. 1963 Oct 19;2(5363):965-70. [PubMed
]
- Phelan KM, Mosholder AD, Lu S: Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003 Nov;64(11):1328-34. [PubMed
]
- Lum GM, Aisenbrey GA, Dunn MJ, Berl T, Schrier RW, McDonald KM: In vivo effect of indomethacin to potentiate the renal medullary cyclic AMP response to vasopressin. J Clin Invest. 1977 Jan;59(1):8-13. [PubMed
]
- Ragheb M: The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol. 1990 Oct;10(5):350-4. [PubMed
]
- Akbarpour F, Afrasiabi A, Vaziri ND: Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 1985 Jun;78(6):756-7. [PubMed
]
- Drugs.com

- Wikipedia

- RxList

|
| Organisms Affected |
|
| Phase 1 Metabolizing Enzymes |
- Cytochrome P450 2C19 (CYP2C19)
- UDP-glucuronosyltransferase 1-9 (UGT1A9)
|
| Targets |
- Prostaglandin G/H synthase 1
- Prostaglandin G/H synthase 2
|
|
Drug Target 1
[top]
|
| Target 1 ID |
20 |
| Target 1 Name |
Prostaglandin G/H synthase 1 |
| Target 1 Synonyms |
- COX-1
- Cyclooxygenase- 1
- EC 1.14.99.1
- PGH synthase 1
- PGHS-1
- PHS 1
- Prostaglandin G/H synthase 1 precursor
- Prostaglandin H2 synthase 1
- Prostaglandin-endoperoxide synthase 1
|
| Target 1 Gene Name |
PTGS1 |
| Target 1 Protein Sequence |
>Prostaglandin G/H synthase 1 precursor
MSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR
TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS
NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF
LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ
YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY
ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF
DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA
LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL
VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS
PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL
|
| Target 1 Number of Residues |
608 |
| Target 1 Molecular Weight |
68657 |
| Target 1 Theoretical pI |
7.39 |
| Target 1 GO Classification |
|
Function
|
antioxidant activity
peroxidase activity |
|
Process
|
| Not Available |
|
Component
|
| Not Available |
|
| Target 1 General Function |
Involved in peroxidase activity |
| Target 1 Specific Function |
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells |
| Target 1 Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Prostaglandin and leukotriene metabolism |
|
map00590  |
|
| Target 1 Reactions |
- arachidonate + AH2 + 2 O2 = prostaglandin H2 + A + H2O
|
| Target 1 Pfam Domain Function |
|
| Target 1 Signals |
|
| Target 1 Transmembrane Regions |
|
| Target 1 Essentiality |
Non-Essential |
| Target 1 GenBank ID Protein |
387018  |
| Target 1 UniProtKB/Swiss-Prot ID |
P23219  |
| Target 1 UniProtKB/Swiss-Prot Entry Name |
PGH1_HUMAN  |
| Target 1 PDB ID |
Not Available |
| Target 1 Cellular Location |
- Microsome
- microsomal membrane
- peripheral membrane protein
|
| Target 1 Gene Sequence |
>1800 bp
ATGAGCCGGAGTCTCTTGCTCCGGTTCTTGCTGTTGCTGCTCCTGCTCCCGCCGCTCCCC
GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC
CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC
ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA
CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG
TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCTCCTGGTACTCACAGTGCGCTCC
AACCTTATCCCCAGTCCCCCCACCTACAACTCTGCACATGACTACATCAGCTGGGAGTCT
TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA
CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC
CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT
GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC
AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG
TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG
TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC
CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT
GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC
ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC
AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT
GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCACGGAGTTC
AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG
TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC
CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC
CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG
CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC
GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG
GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT
ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT
CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG
GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT
GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA
|
| Target 1 GenBank Gene ID |
|
| Target 1 GeneCard ID |
PTGS1  |
| Target 1 GenAtlas ID |
PTGS1  |
| Target 1 HGNC ID |
HGNC:9604  |
| Target 1 Chromosome Location |
9 |
| Target 1 Locus |
9q32-q33.3 |
| Target 1 SNPs |
SNPJam Report  |
| Target 1 General References |
- Diaz A, Reginato AM, Jimenez SA: Alternative splicing of human prostaglandin G/H synthase mRNA and evidence of differential regulation of the resulting transcripts by transforming growth factor beta 1, interleukin 1 beta, and tumor necrosis factor alpha. J Biol Chem. 1992 May 25;267(15):10816-22. [PubMed
]
- Takahashi Y, Ueda N, Yoshimoto T, Yamamoto S, Yokoyama C, Miyata A, Tanabe T, Fuse I, Hattori A, Shibata A: Immunoaffinity purification and cDNA cloning of human platelet prostaglandin endoperoxide synthase (cyclooxygenase). Biochem Biophys Res Commun. 1992 Jan 31;182(2):433-8. [PubMed
]
- Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA: Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991 Jun;5(9):2304-12. [PubMed
]
- Yokoyama C, Tanabe T: Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun. 1989 Dec 15;165(2):888-94. [PubMed
]
|
| Target 1 Drug References |
- Higuchi K, Tominaga K, Watanabe T, Uno H, Shiba M, Sasaki E, Tanigawa T, Takashima T, Hamaguchi M, Oshitani N, Matsumoto T, Iwanaga Y, Fukuda T, Fujiwara Y, Arakawa T: Indomethacin, but not Helicobacter pylori, inhibits adaptive relaxation in isolated guinea-pig stomach. Drugs Exp Clin Res. 2004;30(5-6):235-41. [PubMed
]
- Bobadilla L RA, Perez-Alvarez V, Bracho Valdes I, Lopez-Sanchez P: Effect of pregnancy on the roles of nitric oxide and prostaglandins in 5-hydroxytryptamine-induced contractions in rat isolated thoracic and abdominal aorta. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):202-9. [PubMed
]
- Fornai M, Blandizzi C, Colucci R, Antonioli L, Bernardini N, Segnani C, Baragatti B, Barogi S, Berti P, Spisni R, Del Tacca M: Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May;54(5):608-16. [PubMed
]
- Moth CW, Prusakiewicz JJ, Marnett LJ, Lybrand TP: Stereoselective binding of indomethacin ethanolamide derivatives to cyclooxygenase-1. J Med Chem. 2005 May 19;48(10):3613-20. [PubMed
]
- Kundu N, Walser TC, Ma X, Fulton AM: Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005 Oct;54(10):981-7. Epub 2005 May 13. [PubMed
]
|
|
Drug Target 2
[top]
|
| Target 2 ID |
290 |
| Target 2 Name |
Prostaglandin G/H synthase 2 |
| Target 2 Synonyms |
- COX-2
- Cyclooxygenase- 2
- EC 1.14.99.1
- PGH synthase 2
- PGHS-2
- PHS II
- Prostaglandin G/H synthase 2 precursor
- Prostaglandin H2 synthase 2
- Prostaglandin-endoperoxide synthase 2
|
| Target 2 Gene Name |
PTGS2 |
| Target 2 Protein Sequence |
>Prostaglandin G/H synthase 2 precursor
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL
|
| Target 2 Number of Residues |
614 |
| Target 2 Molecular Weight |
68997 |
| Target 2 Theoretical pI |
7.41 |
| Target 2 GO Classification |
|
Function
|
antioxidant activity
peroxidase activity |
|
Process
|
| Not Available |
|
Component
|
| Not Available |
|
| Target 2 General Function |
Involved in peroxidase activity |
| Target 2 Specific Function |
May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity |
| Target 2 Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Prostaglandin and leukotriene metabolism |
|
map00590  |
|
| Target 2 Reactions |
- arachidonate + AH2 + 2 O2 = prostaglandin H2 + A + H2O
|
| Target 2 Pfam Domain Function |
|
| Target 2 Signals |
|
| Target 2 Transmembrane Regions |
|
| Target 2 Essentiality |
Non-Essential |
| Target 2 GenBank ID Protein |
291988  |
| Target 2 UniProtKB/Swiss-Prot ID |
P35354  |
| Target 2 UniProtKB/Swiss-Prot Entry Name |
PGH2_HUMAN  |
| Target 2 PDB ID |
Not Available |
| Target 2 Cellular Location |
- Microsome
- microsomal membrane
- peripheral membrane protein
|
| Target 2 Gene Sequence |
>1815 bp
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG
|
| Target 2 GenBank Gene ID |
|
| Target 2 GeneCard ID |
PTGS2  |
| Target 2 GenAtlas ID |
PTGS2  |
| Target 2 HGNC ID |
HGNC:9605  |
| Target 2 Chromosome Location |
1 |
| Target 2 Locus |
1q25.2-q25.3 |
| Target 2 SNPs |
SNPJam Report  |
| Target 2 General References |
- Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7384-8. [PubMed
]
- Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T: Structure of the human cyclo-oxygenase-2 gene. Biochem J. 1994 Sep 15;302 ( Pt 3):723-7. [PubMed
]
- Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, Tanabe T: Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 1994 May 1;221(3):889-97. [PubMed
]
- Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM: Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem. 1993 Apr 25;268(12):9049-54. [PubMed
]
|
| Target 2 Drug References |
- Jerde TJ, Calamon-Dixon JL, Bjorling DE, Nakada SY: Celecoxib inhibits ureteral contractility and prostanoid release. Urology. 2005 Jan;65(1):185-90. [PubMed
]
- Pilane CM, Labelle EF: Nitric oxide stimulated vascular smooth muscle cells undergo apoptosis induced in part by arachidonic acid derived eicosanoids. J Cell Physiol. 2005 Aug;204(2):423-7. [PubMed
]
- Zhang GS, Fu YB, Xia M: [Proliferation inhibition effect of indomethacin on CML cells associated with down-regulation of phosphorylated STAT1/STAT5 and inhibition of COX-2 expression.] Zhonghua Xue Ye Xue Za Zhi. 2004 Dec;25(12):732-5. [PubMed
]
- Armstrong PJ, Franklin DP, Carey DJ, Elmore JR: Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg. 2005 Mar;19(2):248-57. [PubMed
]
- Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K: Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther. 2005 Jul;314(1):302-9. Epub 2005 Apr 14. [PubMed
]
|